Swelling

Kirigami hydrogels rise from cellulose film

Retrieved on: 
Freitag, April 12, 2024
Science, Nanofiber, Gel, University of Tokyo, Swelling, Administration, Hydrogel, Research, Kirigami, Water, The Journal, Cellulose, Tissue engineering, Movement, Growth, Advanced Materials

Their work extends the emerging field of 'kirigami hydrogels', in which patterns are cut into a thin film allowing it to later swell into complex hydrogel structures.

Key Points: 
  • Their work extends the emerging field of 'kirigami hydrogels', in which patterns are cut into a thin film allowing it to later swell into complex hydrogel structures.
  • Researchers Daisuke Nakagawa and Itsuo Hanasaki worked with an initially dry film composed of nanofibers of cellulose, the natural material that forms much of the structure of plant cell walls.
  • They used laser processing to cut structures into the film before water was added allowing the film to swell.
  • The advance in kirigami hydrogels achieved by the TUAT team significantly extends the options for future hydrogel applications.

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Dienstag, Mai 7, 2024
Angioedema, FDA, Mouth, NDA, Food, Swelling, Skin, Research, Attention deficit hyperactivity disorder, Insurance, Trial of the century, ADHD, Lennox–Gastaut syndrome, Dermatology, Seizure, Prescription, Public expenditure, Riluzole, Vomiting, Patent, Patient, Adrenaline, Common stock, Anaphylaxis, Epilepsy, Diazepam, PD, Therapy, Serdexmethylphenidate/dexmethylphenidate, Type, Pharmaceutical industry

“We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • Total revenues increased to $12.1 million in the first quarter 2024 from $11.1 million in the first quarter 2023.
  • Research and development expenses increased to $5.9 million in the first quarter 2024 from $3.5 million in the first quarter 2023.
  • Non-GAAP adjusted EBITDA loss was $7.2 million in the first quarter 2024, compared to non-GAAP adjusted EBITDA loss of $3.9 million in the first quarter 2023.

New Report: How E-Bike Awareness Gaps and Behavior Increase Battery Fire Risks

Retrieved on: 
Dienstag, Mai 7, 2024
Fire department, UL, Risk, Fire, Safety, Swelling, Engagement, City, Death, Personal, Research, Habit, Injury, Lime, Electricity, Standard, Crash, Growth, Electric battery

San Francisco tells a similar story, with 215 battery fires documented since e-bikes and e-scooters gained popularity there in 2017.

Key Points: 
  • San Francisco tells a similar story, with 215 battery fires documented since e-bikes and e-scooters gained popularity there in 2017.
  • As more Americans choose to ride, the safety awareness deficit needs to be understood and reduced.
  • UL Standards & Engagement has more than 80 standards developed in their portfolio that address lithium-ion battery risks, offering a layer of protection for consumers.
  • “This commitment to safety is why it's critical that we test our proprietary battery design against the most rigorous safety standards.

Seat Occupancy Sensors and Gaming - IDTechEx Explores Printed and Flexible Sensors

Retrieved on: 
Freitag, Mai 3, 2024
System, Glass, Temperature, Swelling, Flexible, Market, Heart rate, Tablet, Pressure, Growth, Overheating, Players

They measure all sorts of variables from touch, temperature, and heart rate across many different sectors, which IDTechEx's report " Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets " explores in detail.

Key Points: 
  • They measure all sorts of variables from touch, temperature, and heart rate across many different sectors, which IDTechEx's report " Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets " explores in detail.
  • Battery health monitoring in electric vehicles using multi-functional hybrid sensors is an emerging role for printed and flexible sensors.
  • Gaming controllers and inputs could be revolutionized with printed flexible 3D force sensors.
  • To find out more about the IDTechEx report "Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets", including downloadable sample pages, please visit www.IDTechEx.com/flexsensors .

Seat Occupancy Sensors and Gaming - IDTechEx Explores Printed and Flexible Sensors

Retrieved on: 
Freitag, Mai 3, 2024
System, Glass, Temperature, Swelling, Flexible, Market, Heart rate, Tablet, Pressure, Growth, Overheating, Players

They measure all sorts of variables from touch, temperature, and heart rate across many different sectors, which IDTechEx's report " Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets " explores in detail.

Key Points: 
  • They measure all sorts of variables from touch, temperature, and heart rate across many different sectors, which IDTechEx's report " Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets " explores in detail.
  • Battery health monitoring in electric vehicles using multi-functional hybrid sensors is an emerging role for printed and flexible sensors.
  • Gaming controllers and inputs could be revolutionized with printed flexible 3D force sensors.
  • To find out more about the IDTechEx report "Printed and Flexible Sensors 2024-2034: Technologies, Players, Markets", including downloadable sample pages, please visit www.IDTechEx.com/flexsensors .

"A New Era in Venous Care: Bowie Welcomes Vein Treatment Clinic"

Retrieved on: 
Dienstag, April 30, 2024
Radiofrequency ablation, Mouth ulcer, Patient, RFA, Swelling, Education, Vein, Oberlin College, Itch, Varicose veins, Female, Environment, Physician, Weight, Cramp, General surgery

BOWIE, Md., April 30, 2024 /PRNewswire/ -- A pioneering vein treatment facility, Vein Treatment Clinic is delighted to announce its grand opening in Bowie, Maryland , offering revolutionary vascular care and innovative treatment solutions to the community.

Key Points: 
  • BOWIE, Md., April 30, 2024 /PRNewswire/ -- A pioneering vein treatment facility, Vein Treatment Clinic is delighted to announce its grand opening in Bowie, Maryland , offering revolutionary vascular care and innovative treatment solutions to the community.
  • Vein Treatment Clinic is dedicated to the comprehensive management and treatment of various venous disorders, including varicose veins, spider veins, venous ulcers, and more.
  • Per Dr. Kamran Saraf, "At the Vein Treatment Clinic, we are committed to excellence in vein care with minimal discomfort or downtime."
  • For additional information about the Vein Treatment Clinic or to book a consultation, please visit www.veintreatmentclinic.com or contact the clinic directly at 240-219-8778.

Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Retrieved on: 
Montag, April 29, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Other Health, Dermatitis, Itch, Pain, Shanda, Skin, Inflammation, Food, Swelling, Stinger, Rash, Body surface area, Nose, Agency, Atopic dermatitis, Folliculitis, Common, Therapy, PDUFA, Incidence, Patient, Psoriasis, Red, Headache, Irritation, Ageing, Pharmaceutical industry

The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.

Key Points: 
  • The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.
  • On May 24, 2022, Dermavant announced the FDA approved VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Retrieved on: 
Mittwoch, April 17, 2024
Health, FDA, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pain, American Academy, Phase, ARR, OCR, News, Blood, Swelling, Food, ROG, American Academy of Neurology, Erythema, Inflammation, Roche, Disease, Patient, RMS, Neurology, AAN, EMA, Itch, MRI, PPMS, Irritation, Annual general meeting, Food and Drug Administration, European Medicines Agency, Disability, Pharmaceutical industry

Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation.

Key Points: 
  • Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation.
  • “Updated results from OCARINA II further underline the potential benefits of subcutaneous Ocrevus for patients with both relapsing and progressive forms of MS,” said Scott Newsome, D.O., lead author, Johns Hopkins University School of Medicine.
  • “Patients treated with subcutaneous Ocrevus experienced appropriate B-cell suppression and impressive near-complete suppression of new inflammatory disease activity.
  • There are more than 30 ongoing Ocrevus clinical trials designed to help us better understand MS and its progression.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
Mittwoch, April 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Mittwoch, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management